Navigation Links
King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide

BRISTOL, Tenn.--(BUSINESS WIRE)--Apr 19, 2007 - King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company has positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the Company's ALTACE(R) (ramipril) diuretic fixed-dose combination product. The Company is continuing to evaluate the trial data and expects to present the findings in detail at an upcoming scientific conference.

About King Pharmaceuticals

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

Forward-looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the expected presentation of Phase III results for the Company's ALTACE(R) diuretic combination product at an upcoming scientific conference. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause actual results to differ materially from the forward-looking statements include dependence on King's ability to present the Phase III results for its ALTACE(R) diuretic combination product as planned; and dependence on the final outcome of the Company's review of the data. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in th e "Risk Factors" section and other sections of King's Form 10-K for the year ended December 31, 2006, which is on file with the U.S. Securities and Exchange Commission. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

Contact

King Pharmaceuticals, Inc., Bristol
James E. Green, 423-989-8125
Executive Vice President, Corporate Affairs
or
David E. Robinson, 423-989-7045
Senior Director, Corporate Affairs


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... May 22, 2017  As the specialty pharmacy ... continue to make the revolutionary shift from volume-based ... for ensuring positive patient outcomes and shaping the ... shifting focus away from clinical trials and toward ... long-term specialty drug therapy utilization in precise patient ...
(Date:5/12/2017)... , May 12, 2017  The China and Canada ... technology that consumes less water, energy and detergent, and features a ... product LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s ... ... LaughingU, is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
(Date:5/23/2017)... Newport Beach, CA (PRWEB) , ... May 23, ... ... Board Certified Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to ... patients interested in building collagen and elastin in their face, neck, and body ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are now welcome ... in Mt. Pleasant, SC, with or without a referral. A full mouth reconstruction can ... missing teeth in Charleston, SC. Those who suffer from gum disease, misaligned teeth ...
(Date:5/23/2017)... Mt. Horeb, WI (PRWEB) , ... May 23, 2017 , ... ... now invited to call Dr. Angela Cotey’s practice to schedule an appointment, with or ... dentistry services, and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, ... a pen. "My wife’s hand was damaged in a firework accident, so she couldn’t ... people with manual problems." , He then designed and created a prototype for the ...
Breaking Medicine News(10 mins):